The COVID-19 pandemic has highlighted the necessity of finding health solutions in an unprecedentedly short length of time. However, the first treatments, tests and vaccines will only offer partial solutions. Competing follow-on technologies will offer better or complementary health benefits. It is essential that health systems do not put all of their eggs in one basket.

On the occasion of Adam Wagstaff’s death, Professor Tony Culyer reflects on his vast legacy to health economics, from Tony’s perspective of having been Adam’s PhD supervisor as well as a friend and collaborator.

A move towards paying multiple prices for medicines (depending on what they are used for) could address a commonly cited problem in drug development and increase patient access. Our latest consulting report investigates whether key stakeholders are onboard.